Agios Pharmaceuticals (AGIO) Stock: Buy, Sell, or Hold?
AGIO - Agios Pharmaceuticals, Inc.
$37.19
0.01 (0.03%)
▲
5d:
+15.07%
30d:
+8.77%
90d:
+2.28%
WAIT
LOW Confidence
Analysis Updated: Oct 22, 2026 12:00 AM ET
Earnings: Nov 05, 2026
13d
Get Alerted When AGIO Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 MIXED SIGNALS: AGIO shows conflicting indicators. Wait for confirmation before entering.
📊 MIXED SIGNALS: AGIO shows conflicting indicators. Wait for confirmation before entering.
In-depth Analysis How we analyze
Valuation Analysis: AGIO is currently trading at $37.19, which is considered extended relative to its 30-day fair value range of $31.40 to $34.16.
Technical Outlook: Technically, AGIO is showing sideways momentum. The price is approaching resistance at $37.74. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation.
Market Sentiment: AGIO scores 15/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $46.00 (+23.7%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, AGIO is showing sideways momentum. The price is approaching resistance at $37.74. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation.
Market Sentiment: AGIO scores 15/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $46.00 (+23.7%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
EXTENDED
Historical Trading Range
$31.40 -
$34.16
Company Quality Score
45/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
21.1%
All Signals
- BEARISH: Price extended above range (+8.9% above its trading range)
- BEARISH: Weak technical setup (15/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 23.7% below Wall St target ($46.00)
- WARNING: Composite score 45/100 in the bottom quintile — this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$31.40 -
$34.16
Current vs Trading Range
EXTENDED
Support & Resistance Levels
Support Level
$29.67
Resistance Level
$37.74
Current Trend
Sideways
Technical data as of
Oct 22, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-9.95
Wall Street Target
$46.00
(+23.7%)
Revenue Growth (YoY)
259.3%
Share & Embed Analysis
Last updated: October 22, 2026 6:08 PM ET
Data refreshes hourly during market hours. Next update: 7:08 PM
Data refreshes hourly during market hours. Next update: 7:08 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is AGIO showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
BMRN
Biomarin Pharmaceutical … |
STRONG BUY
28 analysts |
$92 | 67 BUY |
|
BBIO
BridgeBio Pharma Inc |
STRONG BUY
23 analysts |
$108 | 58 HOLD |
|
DNLI
Denali Therapeutics Inc |
STRONG BUY
20 analysts |
$36 | 68 BUY |
|
INCY
Incyte Corporation |
HOLD
28 analysts |
$130 | 77 BUY |
|
AXSM
Axsome Therapeutics Inc |
STRONG BUY
22 analysts |
$283 | 49 HOLD |
